
According to Validea's guru fundamental report, Thermo Fisher Scientific (TMO) is rated highly (62%) using their John Neff-based Low PE Investor model, which favors firms with persistent earnings growth trading at a discount. While TMO passes tests for EPS growth, future EPS growth, sales growth, free cash flow, and EPS persistence, it fails the P/E ratio and Total Return/PE tests, indicating mixed valuation signals based on Neff's strategy.
Thermo Fisher Scientific Inc. (TMO), a large-cap growth stock within the Medical Equipment & Supplies sector, has been evaluated by Validea's Low PE Investor model, inspired by John Neff's strategy, receiving a 62% rating. This model favors companies exhibiting persistent earnings growth that are priced at a discount relative to their earnings growth and dividend yield. TMO demonstrates positive underlying fundamentals, passing tests for EPS growth, future EPS growth, sales growth, free cash flow, and EPS persistence. However, the company fails the model's P/E ratio and Total Return/PE criteria, indicating potential valuation concerns from a Neff perspective. A score of 62% falls below the 80% threshold that typically signifies Validea's model interest, suggesting that while fundamentally sound in growth aspects, its current valuation does not align strongly with this specific value-oriented strategy. The overall moderately negative sentiment associated with the report (-0.4 for the article, -0.2 for TMO) reflects this mixed assessment of strong growth fundamentals against less favorable valuation metrics under the Neff framework.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately negative
Sentiment Score
-0.40
Ticker Sentiment